BREAST CANCER CHEMOTHERAPY RESPONSE IN WAHIDIN SUDIROHUSODO HOSPITAL, MAKASSAR
DOI:
https://doi.org/10.20956/nmsj.v0i1.2202Abstract
ABSTRACT
Introduction: Treatments of breast cancer are multidisciplinary. Chemotherapy is
one of the most important modalities and has become the standard of breast cancer
treatment of in the adjuvant or neoadjuvant setting. Evaluation is needed in order to
understand the effectivity of the chemotherapy regiment, to improve the service
system and to share with other centers. Objectives: to understand the
characteristics of chemotherapy patients, types of regimen, settings chemotherapy
and neoadjuvant chemotherapy response of breast cancer. Methods: A
retrospective study was done by reviewing the administrative data of cancer patients
who were treated in the surgical oncology Wahidin Sudirohusodo Hospital, Makassar
in 2014. Results: During 2014 has been carried out chemotherapy for 247 breast
cancer patients, used as neoadjuvan setting 145 cases (59 %) and Adjuvan 102
cases (41%). The regimen used are CAF 155 cases ( 63%), TAC 55 cases ( 22
%), TA 20 cases (8%), GC 11 cases ( 5%), dan Vinoralbine 6 cases (2%).
Cumulative Clinical Response are: complete response 3 cases (2%), partial
response 112 cases (78%), stable disease 23 cases (15%), and progresive disease
9 (5%). Chemoterapy response by subtype: Luminal 67%, Her2 70%, Triple Negatif
88%. Conclusions: Breast cancer clinical response to various chemotherapy
regimens are good, regimen and subtype affect the response to chemotherapy.
Keywords: breast cancer, chemotherapy, clinical response
References
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer
statistics. CA: a cancer journal for clinicians. 2011;61(2):69-90.
Wahidin M, Noviani R, Hermawan S, Andriani V, Ardian A, Djarir H. Population-based cancer registration in Indonesia. Asian Pac J Cancer Prev. 2012;13(4):1709-1710.
Rhodes A, Yip C. Comparison of breast cancer in Indonesia and
Malaysia–a clinico-pathological study between Dharmais Cancer Centre
Jakarta and University Malaya Medical Centre, Kuala Lumpur. Asian Pacific Journal of Cancer Prevention. 2011;12:2943-2946.
Cardoso F, Bedard PL, Winer EP, Pagani O, Senkus-Konefka E, Fallowfield LJ, et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. Journal of the National Cancer Institute. 2009;101(17):1174-1181.
Gong C, Yao H, Liu Q, Chen J, Shi J, Su F, et al. Markers of tumor-initiating
cells predict chemoresistance in breast cancer. PloS one. 2010; 5(12):e15630.
Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer:
an update. Journal of Clinical Oncology. 2006;24(12):1940-1949.
Connolly RM, Stearns V. Current approaches for neoadjuvant chemotherapy in breast cancer. European journal of pharmacology. 2013;717(1):58-66.
Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer. 2009;45(2):228-247.
Denkert C, Sinn BV, Issa Y, Müller BM, Maisch A, Untch M, et al. Prediction of response to neoadjuvant chemotherapy: new biomarker approaches and concepts. Breast Care. 2011;6(4):265-272.
Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients
randomly assigned to cyclophosphamide, methotrexate, and
fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish
Breast Cancer Cooperative Group. Journal of Clinical Oncology. 2005;23(30):7483-7490.
Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. reoperative chemotherapy: updates of national surgical adjuvant
breast and bowel project protocols B- 18 and B-27. Journal of Clinical Oncology. 008;26(5):778-785.
Kong X, Moran MS, Zhang N, Haffty B, Yang Q. Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable
prognosis for breast cancer patients. European Journal of Cancer. 2011;47(14):2084-2090.
Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. Journal
of Clinical Oncology. 1999;17(2):460-.
Luangdilok S, Samarnthai N, Korphaisarn K. Association between Pathological Complete Response and Outcome Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients. Journal of breast cancer. 2014;17(4):376-385.
Youlden DR, Cramb SM, Yip CH, Baade PD. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer biology & medicine. 2014;11(2):101.
Howlader N, Noone A, Krapcho M, Garshell J, Neyman N, Altekruse S, et al. SEER Cancer Statistics Review, 1975-2010.[Based on the November 2012 SEER data submission, posted
to the SEER web site, April 2013.]. Bethesda, MD: National Cancer Institute. 2013.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer. 2010;127(12):2893-2917.
DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA: a cancer journal for clinicians. 2011;61(6):408-418.
Kouame JND, Troh E, Kouakou EK, Doukouré B, Kouame AD, Abouna AD, et al. Epidemiology and Histology Aspects of Breast Cancers of Women in Ivory Coast. Journal of Cancer Therapy. 2012;3(05):782.
Engstrom M, Opdahl S, Hagen A, Romundstad P, Akslen L, Haugen O, et al. Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast cancer research and treatment. 2013;140(3):463-473.
Lv M, Li B, Li Y, Mao X, Yao F, Jin F. Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China. Asian Pacific journal of cancer prevention: APJCP. 2010;12(9):2411-2417.
Parise CA, Caggiano V. Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers.
Journal of cancer epidemiology. 2014;2014.
Haque R, Ahmed SA, Inzhakova G, Shi J, Avila C, Polikoff J, et al. Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiology Biomarkers & Prevention. 2012;21(10):1848-1855.
Kuo W-H, Yen AM-F, Lee P-H, Hou M-F, Chen S-C, Chen K-M, et al. Incidence and risk actors associated with bilateral breast cancer in area with early age diagnosis but low
incidence of primary breast cancer: analysis of 10-year longitudinal cohort in Taiwan. Breast cancer research and treatment. 2006;99(2):221-228.
Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Annals of surgical oncology. 2012;19(5):1508-1516.
Cortazar P, Zhang L, Untch M, Mehta K, Costantino J, Wolmark N, et al. Meta-analysis esults from the collaborative trials in neoadjuvant breast cancer (CTNeoBC). Cancer Research. 2012;72(24 Supplement):S1-11.
Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clinical Cancer Research. 2005;11(16):5678-5685.
